BioMAP Phenotypic Profiling -

Services

BioMAP^® Human Primary Cell Phenotypic Profiling Services

Overview of the BioMAP Platform

BioMAP profiling is the broadest, most physiologically relevant method to quickly and robustly determine the efficacy, safety, and mechanism of action (MOA) of candidate drug molecules to support their pipeline progression.

BioMAP Systems are composed of:

Over 60 human primary cell-based models of tissue and disease biology
Profiling of 100’s of clinically relevant protein biomarkers
Reference benchmark database of 4,500+ reference compound profiles and a suite of bioinformatics-based approaches for in-depth characterization of MOA and predictive insights on efficacy and safety

Request a Quote

BioMAP Phenotypic Profiling Accelerates Candidates from Testing to Therapies

Unparalleled Comparison and Prioritization

Use BioMAP For:

Benchmarking to internal assets and approved standards of care.
Prioritization and rank ordering of candidate small molecules and biologics.
Lead Optimization and Screening of test agents based on physiologically relevant and predictive disease and tissue biology.
Combination Testing to evaluate drug combinations before moving in vivo.

Unmatched Characterization

Use BioMAP For:

Mechanism of Action identification based on machine learning and the largest profile database of its kind.
Indication Selection to ensure the best return on investment for a given molecule.
Repositioning and Repurposing to breathe new life into old assets.
Safety and Cytotoxicity screening using the only phenotypic screen to predict adverse events and identify off-target effects without bias.

Recent Webinars

Combining Target-Based and Phenotypic Discovery Assays for Drug Repurposing Watch Webinar
Immuno-Oncology Drug Development: Profiling Immunomodulatory Biologics and Compounds in Human Primary Cell-Based Oncology Models. Watch Webinar

Recent Client-DiscoverX Co-Publications

A. Hammitzsch, et al., “CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses,” Proceedings of the National Academy of Sciences, vol. 112, no. 34, pp. 10768–10773, 2015. Download PDF
P. Haselmayer, et al., “Characterization of novel PI3Kδ inhibitors as potential therapeutics for SLE and lupus nephritis in pre-clinical studies,” Frontiers in Immunology, vol. 5, 2014. Read Article
J. L. Garrison, et al., “A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum,” Nature, vol. 436, no. 7048, pp. 285–289, 2005. Read Article

Unbiased Characterization

Test Agents Across a Broad Range of Human Disease Models with Diversity PLUS®

The Diversity PLUS panel comprised of 12 BioMAP systems is used to inform on the potency, selectivity, safety, mechanism of action and disease indication of a test agent. A profile of biomarker activity of each test agent is generated and compared against the BioMAP reference database and 19 consensus mechanism class profiles of well-characterized drugs.

Learn More

BioMAP Services Listing

Combo ELECT - Maximize the impact of your compounds in combination
Diversity PLUS - Test agents across a broad range of human disease models
Fibrosis Panel - Model fibrosis in various tissue environments
Oncology Systems - Model complexity of tumor microenvironments
Systems ELECT - Create your own customized BioMAP panel
T Cell/Autoimmune Panel - Model the adaptive immune cell microenvironment

BioMAP Resources

What is BioMAP?

FAQ

Recommended Benchmarks

Application Specific Case Studies

Secondary Activity of an Adrenergic Receptor Antagonist Read Case Study
Economic Impact of BioMAP® Profiling Read Case Study
Explaining a Clinical Adverse Event Read Case Study
Differentiating p38MAPK Inhibitors Read Case Study

BioMAP® Human Primary Cell Phenotypic Profiling Services